{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:51:24Z","timestamp":1691599884251},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00393-019-00733-x","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T18:02:36Z","timestamp":1574964156000},"page":"590-603","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a\u00a0Bayesian network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"79","author":[{"given":"Y. H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. G.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"10","key":"733_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/art.24123","volume":"59","author":"D Aletaha","year":"2008","unstructured":"Aletaha\u00a0D, Landewe\u00a0R, Karonitsch\u00a0T et\u00a0al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations. Arthritis Care Res 59(10):1371\u20131377","journal-title":"Arthritis Care Res"},{"issue":"1","key":"733_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/2046-4053-3-110","volume":"3","author":"S Brown","year":"2014","unstructured":"Brown\u00a0S, Hutton\u00a0B, Clifford\u00a0T et al (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014an overview and application of NetMetaXL. Syst Rev 3(1):110","journal-title":"Syst Rev"},{"issue":"9880","key":"733_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/S0140-6736(13)61115-0","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester\u00a0GR, Benda\u00a0B, Gruben\u00a0D et\u00a0al (2013) Tofacitinib for rheumatoid arthritis\u2014authors\u2019 reply. Lancet 381(9880):1812\u20131813","journal-title":"Lancet"},{"issue":"7521","key":"733_CR4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell\u00a0DM, Ades\u00a0A, Higgins\u00a0J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897","journal-title":"BMJ"},{"issue":"5646","key":"733_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian\u00a0PS, Flanagan\u00a0ME, Ball\u00a0DJ et\u00a0al (2003) Prevention of organ allograft rejection by a\u00a0specific Janus kinase 3 inhibitor. Science 302(5646):875\u2013878","journal-title":"Science"},{"issue":"2","key":"733_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1756-185X.2012.01712.x","volume":"15","author":"MWL Cheung","year":"2012","unstructured":"Cheung\u00a0MWL, Ho\u00a0RC, Lim\u00a0Y et al (2012) Conducting a\u00a0meta-analysis: basics and good practices. Int J Rheum Dis 15(2):129\u2013135","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"733_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","volume":"400","author":"JE Chrencik","year":"2010","unstructured":"Chrencik\u00a0JE, Patny\u00a0A, Leung\u00a0IK et al (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP\u20116. J\u00a0Mol Biol 400(3):413\u2013433","journal-title":"J Mol Biol"},{"key":"733_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2018-214261","volume":"78","author":"B Combe","year":"2019","unstructured":"Combe\u00a0B, Kivitz\u00a0A, Tanaka\u00a0Y et\u00a0al (2019) LB0001 efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Ann Rheum Dis 78:77\u201378","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"733_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias\u00a0S, Welton\u00a0NJ, Sutton\u00a0AJ et\u00a0al (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33(5):641\u2013656","journal-title":"Med Decis Making"},{"key":"733_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2018-214405","volume":"78","author":"MC Genovese","year":"2019","unstructured":"Genovese\u00a0MC, Kalunian\u00a0K, Gottenberg\u00a0J\u2011E et al (2019) FRI0092 safety and efficacy of filgotinib in active rheumatoid arthritis by prior biological DMARD exposure in patients with prior inadequate response or intolerance to biological DMARDS (BDMARD-IR). Ann Rheum Dis 78:709\u2013710","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"733_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"issue":"2","key":"733_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"J Higgins","year":"2012","unstructured":"Higgins\u00a0J, Jackson\u00a0D, Barrett\u00a0J et al (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98\u2013110","journal-title":"Res Synth Methods"},{"issue":"5","key":"733_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg\u00a0MC, Chang\u00a0RW, Dwosh\u00a0I et\u00a0al (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35(5):498\u2013502","journal-title":"Arthritis Rheum"},{"issue":"11","key":"733_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton\u00a0B, Salanti\u00a0G, Caldwell\u00a0DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"6","key":"733_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","volume":"76","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh\u00a0A, Kremer\u00a0J, Ponce\u00a0L et al (2017) Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76(6):1009\u20131019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"733_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer\u00a0J, Li\u00a0ZG, Hall\u00a0S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a\u00a0randomized trial. Ann Intern Med 159(4):253\u2013261","journal-title":"Ann Intern Med"},{"issue":"4","key":"733_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer\u00a0JM, Cohen\u00a0S, Wilkinson\u00a0BE et al (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64(4):970\u2013981","journal-title":"Arthritis Rheum"},{"issue":"4","key":"733_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00393-016-0254-4","volume":"77","author":"Y Lee","year":"2018","unstructured":"Lee\u00a0Y, Bae\u00a0S\u2011C (2018) Comparative efficacy and safety of baricitinib 2\u202fmg and 4\u202fmg in patients with active rheumatoid arthritis. Z\u00a0Rheumatol 77(4):335\u2013342","journal-title":"Z Rheumatol"},{"issue":"3","key":"733_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4078\/jrd.2018.25.3.169","volume":"25","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH (2018) Association between the neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and rheumatoid arthritis and their correlations with the disease activity: a meta-analysis. J\u00a0Rheum Dis 25(3):169\u2013178","journal-title":"J Rheum Dis"},{"issue":"3","key":"733_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3343\/alm.2015.35.3.283","volume":"35","author":"YH Lee","year":"2015","unstructured":"Lee\u00a0YH (2015) Meta-analysis of genetic association studies. Ann Lab Med 35(3):283\u2013287","journal-title":"Ann Lab Med"},{"issue":"4","key":"733_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2017.24.4.211","volume":"24","author":"YH Lee","year":"2017","unstructured":"Lee\u00a0YH, Song\u00a0GG (2017) Comparative efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis: a\u00a0Bayesian network meta-analysis of randomized controlled trials. J\u00a0Rheum Dis 24(4):211\u2013219","journal-title":"J Rheum Dis"},{"key":"733_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer\u00a0DM, Jesson\u00a0MI, Li\u00a0X et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J\u00a0Inflamm (Lond) 7:41","journal-title":"J Inflamm (Lond)"},{"issue":"3","key":"733_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000051263","volume":"12","author":"M Oremus","year":"2001","unstructured":"Oremus\u00a0M, Wolfson\u00a0C, Perrault\u00a0A et\u00a0al (2001) Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer\u2019s disease drug trials. Dement Geriatr Cogn Disord 12(3):232\u2013236","journal-title":"Dement Geriatr Cogn Disord"},{"key":"733_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski\u00a0R Jr (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784\u2013803","journal-title":"Pharmacol Res"},{"issue":"2","key":"733_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti\u00a0G, Ades\u00a0A, Ioannidis\u00a0JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J\u00a0Clin Epidemiol 64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"28","key":"733_CR26","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","volume":"282","author":"C Schindler","year":"2007","unstructured":"Schindler\u00a0C, Levy\u00a0DE, Decker\u00a0T (2007) JAK-STAT signaling: from interferons to cytokines. J\u00a0Biol Chem 282(28):20059\u201320063","journal-title":"J Biol Chem"},{"issue":"5","key":"733_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3904\/kjim.2014.29.5.656","volume":"29","author":"GG Song","year":"2014","unstructured":"Song\u00a0GG, Bae\u00a0S\u2011C, Lee\u00a0YH (2014) Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a\u00a0meta-analysis of randomized controlled trials. Korean J Intern Med 29(5):656","journal-title":"Korean J Intern Med"},{"issue":"12","key":"733_CR28","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s10067-012-2080-7","volume":"31","author":"GG Song","year":"2012","unstructured":"Song\u00a0GG, Bae\u00a0SC, Lee\u00a0YH (2012) Association between vitamin D intake and the risk of rheumatoid arthritis: a\u00a0meta-analysis. Clin Rheumatol 31(12):1733\u20131739","journal-title":"Clin Rheumatol"},{"issue":"5","key":"733_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3904\/kjim.2014.29.5.656","volume":"29","author":"GG Song","year":"2014","unstructured":"Song\u00a0GG, Bae\u00a0SC, Lee\u00a0YH (2014) Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a\u00a0meta-analysis of randomized controlled trials. Korean J Intern Med 29(5):656\u2013663","journal-title":"Korean J Intern Med"},{"issue":"8","key":"733_CR30","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka\u00a0Y, Suzuki\u00a0M, Nakamura\u00a0H et al (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 63(8):1150\u20131158","journal-title":"Arthritis Care Res"},{"issue":"10","key":"733_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/13543784.2017.1372422","volume":"26","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC, Abdul Azeez\u00a0M, Kiriakidis\u00a0S (2017) Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 26(10):1181\u20131187","journal-title":"Expert Opin Investig Drugs"},{"issue":"24","key":"733_CR32","first-page":"2120","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor\u00a0K (2012) FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 69(24):2120","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"733_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G Valkenhoef","year":"2012","unstructured":"Valkenhoef\u00a0G, Lu\u00a0G, Brock\u00a0B et al (2012) Automating network meta-analysis. Res Synth Methods 3(4):285\u2013299","journal-title":"Res Synth Methods"},{"issue":"3","key":"733_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde\u00a0D, Tanaka\u00a0Y, Fleischmann\u00a0R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a\u00a0twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559\u2013570","journal-title":"Arthritis Rheum"},{"issue":"7","key":"733_CR35","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","volume":"191","author":"L Van Rompaey","year":"2013","unstructured":"Van Rompaey\u00a0L, Galien\u00a0R, van der Aar\u00a0EM et\u00a0al (2013) Preclinical characterization of GLPG0634, a\u00a0selective inhibitor of JAK1, for the treatment of inflammatory diseases. J\u00a0Immunol 191(7):3568\u20133577","journal-title":"J Immunol"},{"issue":"6","key":"733_CR36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven\u00a0RF, Fleischmann\u00a0R, Cohen\u00a0S et\u00a0al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N\u00a0Engl J Med 367(6):508\u2013519","journal-title":"N Engl J Med"},{"key":"733_CR37","first-page":"259","volume":"78","author":"R Westhovens","year":"2019","unstructured":"Westhovens\u00a0R, Rigby\u00a0W, van der Heijde\u00a0D et\u00a0al (2019) LB0003 efficacy and safety of filgotinib for patients with rheumatoid arthritis na\u00efve to methotrexate therapy: FINCH3 primary outcome results. Ann Rheum Dis 78:259\u2013261","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"733_CR38","first-page":"534","volume":"69","author":"R Westhovens","year":"2017","unstructured":"Westhovens\u00a0R, van der Aa\u00a0A, Jamoul\u00a0C et al (2017) Effect of baseline MTX dose on clinical efficacy and safety in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from a\u00a0phase 2B study. Arthritis Rheumatol 69(Suppl 10):534","journal-title":"Arthritis Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00733-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-00733-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00733-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T01:14:57Z","timestamp":1606439697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-00733-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-00733-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"28 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.\u00a0H.\u00a0Lee and G.\u00a0G.\u00a0Song declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}